Nexalin technology awarded key patent related to its non-invasive, frequency-based deep-brain stimulation device for the treatment of alzheimer's and dementia

Houston, texas, june 20, 2024 (globe newswire) -- nexalin technology, inc. (nasdaq: nxl; nxliw) (the “company” or “nexalin”) today announced that the united states patent and trademark office (uspto) has awarded u.s. patent no 12,011,591 relating to the company's non-invasive deep intracranial frequency stimulation (difs®) medical device for the treatment of alzheimer's and other dementia-related brain diseases.  the newly issued patent entitled, “transcranial alternating current dynamic frequency stimulation (tacs) method for alzheimer's and dementia,” relates to the company's gen-2 and gen-3 brain stimulation medical device that administers a proprietary frequency based waveform that is designed to effectively treat patients in a pain free and undetectable manner.
NXL Ratings Summary
NXL Quant Ranking